ATE273979T1 - Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis - Google Patents
Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosisInfo
- Publication number
- ATE273979T1 ATE273979T1 AT01907784T AT01907784T ATE273979T1 AT E273979 T1 ATE273979 T1 AT E273979T1 AT 01907784 T AT01907784 T AT 01907784T AT 01907784 T AT01907784 T AT 01907784T AT E273979 T1 ATE273979 T1 AT E273979T1
- Authority
- AT
- Austria
- Prior art keywords
- osteoporosis
- treatment
- xanthine derivatives
- intermediate products
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0001845A FR2804958B1 (fr) | 2000-02-15 | 2000-02-15 | Derives de xanthine, leur procede de preparation et les intermediaires de ce procede, leur application comme medicament et les compositions pharmaceutiques les renfermant |
PCT/FR2001/000420 WO2001060824A1 (fr) | 2000-02-15 | 2001-02-14 | Derives de xanthine, intermediaires et application au traitement de l'osteoporose |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE273979T1 true ATE273979T1 (de) | 2004-09-15 |
Family
ID=8847004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01907784T ATE273979T1 (de) | 2000-02-15 | 2001-02-14 | Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1257552B1 (de) |
AT (1) | ATE273979T1 (de) |
AU (1) | AU2001235668A1 (de) |
DE (1) | DE60104986T2 (de) |
DK (1) | DK1257552T3 (de) |
ES (1) | ES2227134T3 (de) |
FR (1) | FR2804958B1 (de) |
PT (1) | PT1257552E (de) |
WO (1) | WO2001060824A1 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004009091A1 (en) | 2002-06-17 | 2004-01-29 | Glaxo Group Limited | Purine derivatives as liver x receptor agonists |
NZ613219A (en) | 2008-01-04 | 2014-11-28 | Intellikine Llc | Heterocyclic containing entities, compositions and methods |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
UA115767C2 (uk) | 2011-01-10 | 2017-12-26 | Інфініті Фармасьютікалз, Інк. | Способи отримання ізохінолінонів і тверді форми ізохінолінонів |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
WO2015003881A1 (en) * | 2013-07-08 | 2015-01-15 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
KR20190033526A (ko) | 2016-06-24 | 2019-03-29 | 인피니티 파마슈티칼스, 인코포레이티드 | 병용 요법 |
CN109503583A (zh) * | 2018-12-14 | 2019-03-22 | 南京纽邦生物科技有限公司 | 1,7-二甲基黄嘌呤及其中间体的制备方法、中间体 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE176470T1 (de) * | 1990-10-18 | 1999-02-15 | Kyowa Hakko Kogyo Kk | Xanthinderivate |
EP0825993A1 (de) * | 1995-05-19 | 1998-03-04 | Chiroscience Limited | Xanthine und ihre therapeutische anwendung |
JPH09169665A (ja) * | 1995-12-21 | 1997-06-30 | Kenichi Miyamoto | 骨粗鬆症治療剤 |
SI0812844T1 (en) * | 1996-06-07 | 2003-02-28 | Hoechst Aktiengesellschaft | Use of theophyllin derivatives for the treatment and prophylaxis fo shock conditions, novel xanthine compounds and processes for the production thereof |
GB9703044D0 (en) * | 1997-02-14 | 1997-04-02 | Glaxo Group Ltd | Phenyl xanthine esters and amides |
JPH1192379A (ja) * | 1997-07-24 | 1999-04-06 | Kunio Takaoka | 骨疾患の予防または治療剤 |
-
2000
- 2000-02-15 FR FR0001845A patent/FR2804958B1/fr not_active Expired - Fee Related
-
2001
- 2001-02-14 WO PCT/FR2001/000420 patent/WO2001060824A1/fr active IP Right Grant
- 2001-02-14 EP EP01907784A patent/EP1257552B1/de not_active Expired - Lifetime
- 2001-02-14 AU AU2001235668A patent/AU2001235668A1/en not_active Abandoned
- 2001-02-14 ES ES01907784T patent/ES2227134T3/es not_active Expired - Lifetime
- 2001-02-14 DE DE60104986T patent/DE60104986T2/de not_active Expired - Lifetime
- 2001-02-14 DK DK01907784T patent/DK1257552T3/da active
- 2001-02-14 PT PT01907784T patent/PT1257552E/pt unknown
- 2001-02-14 AT AT01907784T patent/ATE273979T1/de active
Also Published As
Publication number | Publication date |
---|---|
EP1257552B1 (de) | 2004-08-18 |
FR2804958A1 (fr) | 2001-08-17 |
DE60104986D1 (de) | 2004-09-23 |
ES2227134T3 (es) | 2005-04-01 |
PT1257552E (pt) | 2005-01-31 |
WO2001060824A1 (fr) | 2001-08-23 |
AU2001235668A1 (en) | 2001-08-27 |
DE60104986T2 (de) | 2005-08-25 |
DK1257552T3 (da) | 2004-12-20 |
EP1257552A1 (de) | 2002-11-20 |
FR2804958B1 (fr) | 2005-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE235459T1 (de) | Derivate von aminosäuren, sie enthaltende pharmazeutische zusammensetzungen sowie deren herstellunsgverfahren | |
AR024390A1 (es) | Nuevos compuestos | |
ATE202702T1 (de) | Verwendung von oestrogenagonisten und - antagonisten zur herstellung eines medikaments zur behandlung von atherosklerose, unabhängig von lipidsenkung | |
DE68914292T2 (de) | Zusammensetzung zur Behandlung von ischämischen Störungen in Organen. | |
DE69607650T2 (de) | 2,3,5-trimethyl-hydroxyanilid-derivative, ihre herstellung und ihre theraoeutische verwendung | |
ATE273979T1 (de) | Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis | |
ATE231160T1 (de) | Erythromycin-derivate, ihr verfahren zur herstellung und ihre verwendung als arzneimittel | |
DK0450420T3 (da) | Heterocyclisk substituerede dihydropyridiner, fremgangsmåde til deres fremstilling og deres anvendelse i lægemidler | |
BR9610175A (pt) | Composto processo de preparação do composto composição farmacêutica e utilização do composto | |
DK0625153T3 (da) | Nyt isoindolinonderivat, dets fremstilling og farmaceutiske præparater med et indhold deraf | |
ATE308533T1 (de) | Zwischenprodukt und verfahren zur teilsynthese von paclitaxel und dessen analogen | |
ZA939118B (en) | Processes for preparing 2-cyano-3-hydroxy-propenamides and pharmaceutical compositions containing them | |
ATE267832T1 (de) | Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung | |
DK1347965T3 (da) | Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf | |
DE59606725D1 (de) | Substituierte phenylamidine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung | |
BG105247A (en) | N-substituted azabicycloheptane derivatives, production and use thereof | |
DE69002340D1 (de) | Pyrimidin-derivate, 2-(4-(alpha-heteroaryl-alpha-aryl-(alpha-alkyl)-methoxy)-butyl)-1-piperazinyl) mit serotoninergischer wirkung. | |
ATE56437T1 (de) | Verfahren zur herstellung von 1,4dihydropyridinderivaten ueber neue zwischenprodukte. | |
ATE79752T1 (de) | Verwendung von chromanderivaten zur herstellung eines medikamentes zur behandlung von depressiven zustaenden. | |
DE60019723D1 (de) | Eine methode zur herstellung von verbindungen der formel 1 und derivaten | |
AR022044A1 (es) | Derivados de 1,5-benzodiazepina | |
HUP0001127A2 (hu) | Eljárás N-[5-difenil-foszfinoil-metil-4-(4-fluor-fenil)-6-izopropil-pirimidin-2-il]-N-metil-metánszulfonamid előállítására | |
ES2095058T3 (es) | Derivados del 3-azabiciclo(3.2.0)heptano substituidos como productos intermedios. | |
NO305116B1 (no) | Fremgangsmate for fremstilling av C-substituerte dietylentriaminer | |
DE69610331D1 (de) | Neue gylcylanilid-derivate, deren herstellung und deren verwendung zur behandlung von hypercholesterolämie und atherosklerose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1257552 Country of ref document: EP |